ImmunoGenesis
PrivateLast Round
Grant
Dec 4, 2025
Total Funding Raised
$70.7M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
ImmunoGenesis is a biopharmaceutical company that develops immuno-oncology therapeutics designed to enhance immune responses in cold tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmunoGenesis Comparables
Compare ImmunoGenesis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Incendia Therapeutics | 87% | |
| Isosceles Pharmaceuticals | 81% | |
| BioEclipse Therapeutics | 79% |
ImmunoGenesis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 4, 2025 | ||||
| Series A | Apr 1, 2024 | ||||
| VC Round | Jun 27, 2023 | ||||
| Grant | Aug 19, 2020 |
ImmunoGenesis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The University of Texas MD Anderson Cancer Center | VC Round |
| Cancer Focus Fund | Series A, VC Round |
| Cancer Prevention and Research Institute of Texas (CPRIT) | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 17, 2026
Monthly visitors increased 55% MoM.
- Apr 15, 2026
Poster presentation at the AACR 2026 Annual Meeting.
Recent news
Latest coverage and updates
- hiresSep 9, 2026
Immunogenesis, Inc. hired Reza as Board of Directors on Sep 9th '26.
- hiresSep 9, 2026
Immunogenesis, Inc. hired Mike Davis as Board of Directors on Sep 9th '26.
- hiresSep 9, 2026
Immunogenesis, Inc. hired Reza Mazhari as Board of Directors on Sep 9th '26.
- hiresSep 9, 2026
Immunogenesis, Inc. hired Mike as Board of Directors on Sep 9th '26.
ImmunoGenesis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about ImmunoGenesis's valuation, stock price, and market status.
Is ImmunoGenesis a public or private company?
ImmunoGenesis is a private company.
What is the current stock price of ImmunoGenesis?
ImmunoGenesis is a private company with no public stock price. No recent secondary market data is available.
How much is ImmunoGenesis worth (valuation)?
Valuation information for ImmunoGenesis is not publicly available.
Can I buy ImmunoGenesis stock?
ImmunoGenesis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was ImmunoGenesis's last funding round?
ImmunoGenesis's most recent funding round was Grant on December 4, 2025.
Who are the main investors in ImmunoGenesis?
Key investors in ImmunoGenesis include Cancer Focus Fund, Cancer Prevention and Research Institute of Texas (CPRIT).
Will ImmunoGenesis IPO soon?
No public IPO plans have been announced for ImmunoGenesis.
How can I track ImmunoGenesis secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ImmunoGenesis's secondary market activity and sign up for updates.